Efficacy of Oral Nefopam on Multimodal Analgesia in Total Knee Arthroplasty: A Prospective, Double-Blind, Placebo-Controlled, Randomized Trial.

この研究はインパクトが大きい可能性があると判断されました。 OEのAIによるハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文の影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することができ、読者は将来の診療を形成する可能性が最も高い論文に焦点を当てることができます。

研究概要

One hundred patients with knee osteoarthritis undergoing primary total knee arthroplasty were randomized to receive either oral nefopam (40 mg twice daily) alongside celecoxib and pregabalin (n=50) or a placebo alongside the same regimen (n=50). The primary outcome was postoperative consumption of rescue analgesics (oxycodone and morphine). Secondary outcomes included pain scores (VAS) at rest and during motion, knee functional recovery (range of motion and ambulation distance), length of hospital stay, liver function indicators, and complication rates. Outcomes were assessed during hospitalization and within the first 48 hours postoperatively. Overall, the nefopam group showed statistically significant reductions in opioid consumption and pain scores, along with better functional recovery and shorter hospital stays. However, the magnitude of these improvements was not deemed clinically significant. These findings suggest that oral nefopam could provide modest benefits as part of multimodal analgesia for TKA.